Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Preclinical evaluation of macrophage reprogramming in treatment of CTCL

View Full Paper
Ask AI
Bookmark
Share

Authors

MWMadeline WilliamsCPCarla Portocarrero

Discussion

Loading...

Member takes

Overview

Observational analysis indicates tumor growth inhibition in cutaneous T-cell lymphoma via macrophage reprogramming with CD206 and TLR4 modulation.

Key Points

  • Tumor growth reduction was observed when targeting macrophage pathways in cutaneous T-cell lymphoma.
  • Significantly reduced tumor growth was noted in TLR4-deficient mice compared to controls over time with compounded outcomes.
  • Assessment utilized immunofluorescence and scRNA-seq to correlate macrophage markers in cancer cells and skin biopsies.
  • Inhibiting TLR4 and activating CD206 appears to shift macrophages from promoting to suppressing tumor growth.

Cite This Study

Williams et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db5fhttps://doi.org/10.1182/blood-2025-5347
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1MCP-1-CCR2-M2 macrophages axis contributes to diffuse large B-cell lymphoma progression and inhibits antitumor immune response2025 · 6 citations
  2. 2Cutaneous diffuse large B-cell lymphoma induce a macrophage immunosuppressive phenotype through IL-10 secretion2025
  3. 3CDK7 enables adaptive gene transcription required by stromal cells to support distinct T-cell lymphoma phenotypes and represents a novel microenvironment-directed therapeutic target2025
  4. 4Data from Sustained Macrophage Reprogramming Is Required for CD8<sup>+</sup> T cell–Dependent Long-Term Tumor Eradication2025
  5. 5Macrophage repolarization by immune checkpoint blockade drives T-cell engagement in the tumor microenvironment 20762025